{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-145810","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.719506+00:00","generated_at":"2026-06-25T21:46:09.269613+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"UroGen Q1 Jelmyto revenue $13.6M (+81% YoY); net loss $28.4M; cash $137.1M","bullets":["Jelmyto net revenue $13.6M, +81% vs Q1 2021 ($7.5M).","Net loss $28.4M ($1.25/shr) vs $25.9M ($1.17/shr) a year ago.","Cash, cash equivalents & marketable securities $137.1M at Mar 31, up from $89.8M.","Reiterated FY2022 Jelmyto revenue guidance $70-80M and operating expenses $140-160M.","Phase 3 ENVISION trial of UGN-102 enrollment expected to complete by end 2022; NDA submission projected 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-145810","json":"https://secwatch.observer/filing/0001193125-22-145810.json","markdown":"https://secwatch.observer/filing/0001193125-22-145810.md","text":"https://secwatch.observer/filing/0001193125-22-145810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312522145810/0001193125-22-145810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312522145810/d261272d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:46:09.269613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}